Press Releases

Press Releases

    Date Title View
    11/08/22
    Summary ToggleSustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
    PDF Version
    11/05/22
    Summary ToggleData Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
    PDF Version
    11/02/22
    Summary ToggleHorizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
    11/01/22
    Summary ToggleHorizon Therapeutics plc Named to the Seramount Inclusion Index
    PDF Version
    10/27/22
    Summary ToggleQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
    PDF Version
    10/26/22
    Summary ToggleNew Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
    PDF Version
    10/22/22
    Summary ToggleNew Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
    PDF Version
    10/13/22
    Summary ToggleHorizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
    PDF Version
    10/12/22
    Summary ToggleHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
    PDF Version
    10/06/22
    Summary ToggleHorizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
    PDF Version
    Displaying 31 - 40 of 727 results